Core Viewpoint - Dongning Bio is attempting to enter the capital market with a "profit turnaround" narrative, having reported a net profit of 14.257 million yuan in the first three quarters of 2025 after consecutive losses from 2019 to 2022, but faces challenges due to high goodwill of 843 million yuan resulting from aggressive acquisitions [1][2][5]. Financial Performance - In 2023 and 2024, Dongning Bio reported revenues of 814 million yuan and 843 million yuan, with net losses of 315 million yuan and 27.5 million yuan respectively; however, in the first three quarters of 2025, the company achieved a revenue of 658 million yuan and a net profit of 14.257 million yuan [2][4]. - The company's main business segments include biological process solutions and laboratory products and services, with the former contributing over 70% of revenue in recent years [2][3]. Business Segments - The biological process solutions segment generated revenues of 626 million yuan, 638 million yuan, and 507 million yuan from 2023 to September 2025, accounting for 77%, 75.7%, and 77.1% of total revenue respectively; the share of reagent and consumable income increased significantly, reaching 55.4% of total revenue in 2025 [3][4]. - The overseas market has been a key growth driver, with revenues from international operations increasing from 69.52 million yuan in 2023 to 112 million yuan in the first three quarters of 2025, contributing to 17.1% of total revenue [3][4]. Strategic Plans - Dongning Bio plans to use part of the IPO proceeds to expand its global market presence, including establishing local production lines and hiring overseas personnel [4][6]. - The company aims to continue strategic acquisitions and equity investments to enhance its product and service offerings and broaden sales channels [6][7]. Risks and Challenges - The company faces potential risks related to high goodwill of 843 million yuan, which could lead to significant impairment losses if future acquisitions do not meet performance expectations [5][6]. - Despite the positive turnaround in profitability, the sustainability of this profit and the ability to manage goodwill risks remain critical for the company's long-term competitiveness and successful IPO [7].